These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8934381)

  • 21. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
    Wühl E; Mehls O; Schaefer F;
    Kidney Int; 2004 Aug; 66(2):768-76. PubMed ID: 15253732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
    Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; Marcantoni C; de Jong PE; de Zeeuw D; Shahinfar S; Ruggenenti P; Remuzzi G; Levey AS;
    Kidney Int; 2001 Sep; 60(3):1131-40. PubMed ID: 11532109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection.
    Locatelli F; Del Vecchio L; Andrulli S; Colzani S
    Kidney Int Suppl; 2002 Dec; (82):S53-60. PubMed ID: 12410856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
    Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
    Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
    Sasongko TH; Nagalla S; Ballas SK
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009191. PubMed ID: 23543572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Renal side effects of angiotensin converting enzyme inhibitors].
    Schmidt A; Mayer G
    Wien Med Wochenschr; 1996; 146(16):454-6. PubMed ID: 9036683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.
    Jafar TH; Schmid CH; Landa M; Giatras I; Toto R; Remuzzi G; Maschio G; Brenner BM; Kamper A; Zucchelli P; Becker G; Himmelmann A; Bannister K; Landais P; Shahinfar S; de Jong PE; de Zeeuw D; Lau J; Levey AS
    Ann Intern Med; 2001 Jul; 135(2):73-87. PubMed ID: 11453706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal issues in the management of hypertension.
    Hall WD
    Am J Hypertens; 1993 Jul; 6(7 Pt 2):245S-250S. PubMed ID: 8398008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R
    Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on calcium antagonists and the kidney.
    Tobe S
    Curr Opin Nephrol Hypertens; 2003 May; 12(3):309-15. PubMed ID: 12698071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephroprotection by antihypertensive therapy.
    Jacobi J; Schmieder RE
    Basic Res Cardiol; 1998; 93 Suppl 2():109-19. PubMed ID: 9833172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephroprotective effect of antihypertensive drugs in essential hypertension.
    Susic D; Frohlich ED
    J Hypertens; 1998 May; 16(5):555-67. PubMed ID: 9797165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
    Hausberg M; Barenbrock M; Hohage H; Müller S; Heidenreich S; Rahn KH
    Hypertension; 1999 Mar; 33(3):862-8. PubMed ID: 10082500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.